EasyJet Assures No Summer Flight Disruptions from Jet Fuel Shortages Amid Iran War Uncertainty Nicki Minajs Praise of Elon Musk at SpaceX Starbase Event Highlights Celebrity Endorsement Amid Starship V3 Delay Paul Tudor Jones Says There Is No Chance Kevin Warsh Will Get Fed Rate Cuts US Military Aircraft Deployment at Ben Gurion Airport Raises Geopolitical and Defense Industry Questions UK Chancellor Rachel Reeves Seeks to Retain Post Amid Labour Leadership Shift Singapore Refreshed Retail Digital Plan Pushes AI Adoption for Local Retailers HOVR Q1 2026 Earnings EPS Misses Estimates Amid PreRevenue Stage ALB Q1 2026 Earnings Massive EPS Beat of 16682 Surprises Analysts SMCI Q1 2026 Earnings Strong EPS Beat Drives Stock Rally MIRA Q3 2025 Earnings Narrowed Loss Surpasses Expectations Amid No Revenue Global Self Storage Inc SELF Q4 2025 Earnings EPS Falls Short of Estimates as Revenue Details Remain Undisclosed PAGP Q1 2026 Earnings Strong EPS Surprise of 11972 Beats Estimates Masonglory Limited MSGY Holds Steady Near Support as Trading Range Tightens Cable One Inc CABO Surges 965 as Shares Test Key Resistance HUHUTECH Shares Plunge Over 16 as Selling Pressure Mounts New Germany Fund GF Slightly Lower as Price Hovers Near Support Levels Euroseas Ltd ESEA Sees Mild Decline as Shares Approach Key Support Near 61 Robotic Sewing Systems Could Reshape Global Apparel Supply Chains RAIL Q1 2026 Earnings EPS Misses Estimates as Loss Widens Stock Inches Higher Volaris VLRS Surges on Strong Volume Key Levels to Watch After 627 Gain IDT Q1 2026 Earnings EPS Misses Estimates Amid Mixed Operational Performance SW Q1 2026 Earnings EPS Misses Estimates Amid Integration Challenges Stock Edges Higher CARE Q1 2026 Earnings Significant EPS Miss Despite Positive Stock Reaction JOE Q1 2026 Earnings EPS of 024 Meets Expectations Stock Declines Slightly BorgWarner BWA Q1 2026 Earnings EPS Beat Driven by Operational Discipline Shares Edge Higher Grab Group CEO Anthony Tan Takes Top Prize at 41st Singapore Business Awards BLTE Q4 2025 Earnings WiderthanExpected Loss as PreRevenue Biotech Remains Focused on Clinical Development